Related Experiment Video
Updated: Jun 7, 2026
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized
M Le Garff-Tavernier1, J Decocq, C de Romeuf
1INSERM, UMR-S 945, AP-HP, Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique, Paris, France. magali.legarff@psl.aphp.fr
Abstract:
Although anti-CD20 monoclonal antibodies (mAbs) show promise for the treatment of chronic lymphocytic leukemia (CLL), the success of the anti-CD20 mAb rituximab in CLL treatment has been limited. Novel anti-CD20 mAbs with more potent cytotoxic activity have recently been engineered, but so far most have only been tested in vitro with natural killer (NK) cells from healthy donors. Because it is still unclear whether these optimized cytotoxic mAbs will improve NK-cell killing of tumor cells in CLL patients, we characterized the relevant phenotypic and functional features of NK cells from CLL patients in detail. Expression of inhibitory and activating NK-cell receptors and of Fc gamma receptor IIIA (FcγRIIIA) is well preserved in CD16(+)CD56(dim) cytotoxic NK cells from these patients, independently of disease progression. These cells are fully functional following cytokine stimulation. In addition, the FcγRIIIA-optimized LFB-R603 anti-CD20 mAb mediates 100 times greater antibody-dependent cell-mediated cytotoxicity by NK cells from CLL patients and healthy donors than rituximab. Enhanced degranulation against autologous B-CLL cells is observed at lower concentrations of LFB-R603 than rituximab, regardless of CLL prognostic factors. These findings strongly justify further clinical development of anti-CD20 mAbs optimized for FcγR engagement in CLL patients.
Insights
New anti-CD20 antibodies show promise for chronic lymphocytic leukemia (CLL) treatment. Optimized antibodies enhance natural killer (NK) cell killing of CLL cells, suggesting improved therapeutic potential.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Anti-CD20 monoclonal antibodies (mAbs) are investigated for chronic lymphocytic leukemia (CLL) treatment.
- Rituximab's efficacy in CLL is limited.
- Novel anti-CD20 mAbs with enhanced cytotoxicity require evaluation in CLL patients.
Purpose of the Study:
- To characterize the phenotype and function of natural killer (NK) cells in CLL patients.
- To assess the efficacy of Fc gamma receptor IIIA (FcγRIIIA)-optimized anti-CD20 mAbs in CLL.
Main Methods:
- Phenotypic and functional analysis of NK cells from CLL patients.
- In vitro assessment of antibody-dependent cell-mediated cytotoxicity (ADCC) using novel anti-CD20 mAbs and CLL cells.
- Comparison of LFB-R603 and rituximab efficacy.
Main Results:
- NK cells from CLL patients exhibit preserved expression of activating/inhibitory receptors and FcγRIIIA.
- CLL patient NK cells are functional upon cytokine stimulation.
- The FcγRIIIA-optimized LFB-R603 mAb demonstrated 100-fold greater ADCC than rituximab against CLL cells.
- LFB-R603 induced enhanced degranulation at lower concentrations than rituximab.
Conclusions:
- NK cells in CLL patients retain functional capacity for ADCC.
- FcγRIIIA-optimized anti-CD20 mAbs show superior efficacy compared to rituximab.
- These findings support further clinical development of optimized anti-CD20 mAbs for CLL therapy.
